Skip to Content

Effient (prasugrel) Disease Interactions

There are 3 disease interactions with Effient (prasugrel):

Major

Prasugrel (Includes Effient) ↔ bleeding

Severe Potential Hazard, Moderate plausibility. Applies to: Bleeding

Prasugrel is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage, as this agent increases the risk of fatal bleeding.

Major

Prasugrel (Includes Effient) ↔ CAD

Severe Potential Hazard, Moderate plausibility. Applies to: Ischemic Heart Disease, Cerebrovascular Insufficiency

Prasugrel is contraindicated in patients with a history of prior transient ischemic attack (TIA) or stroke. Patients who experience a stroke or TIA while on prasugrel generally should have therapy discontinued. The risk of bleeding is increased in patients receiving prasugrel who undergo coronary artery bypass graft. If possible, prasugrel should be discontinued at least 7 days prior to the procedure.

Moderate

Prasugrel (Includes Effient) ↔ renal/liver disease

Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease, Renal Dysfunction

No dosage adjustment is necessary for patients with renal impairment. No dosage adjustment is necessary in patients with mild to moderate hepatic impairment. Caution should be exercised in patients with end-stage renal disease and those with severe hepatic disease as such patients are generally at higher risk of bleeding.

Effient (prasugrel) drug interactions

There are 251 drug interactions with Effient (prasugrel)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide